If you have spent any time on Indian investing Twitter in the past three years, you have already met the most expensive emotion in money — and it is not greed. It is envy. Greed is a man wanting more. Envy is a man wanting what the person sitting next to him already has. Charlie Munger, in his 1995 Harvard Law School speech The Psychology of Human Misjudgment, ranked envy at number fourteen on his list of twenty-five standard causes of human misjudgment. He went further. In Berkshire’s 2003 annual meeting he said, almost throwing it away, “It’s not greed that drives the world, it’s envy.” That single sentence, written down anywhere else, would be the most uncomfortable thing in a CFA syllabus. In India, in 2026, it is the most accurate.
I want to take this principle apart slowly today, because it explains things that the standard textbook list of biases cannot. It explains why an investor who has compounded at 18% for nine years dumps his entire process and switches to weekly options in month one hundred and nine. It explains why someone with a perfectly diversified small-cap portfolio liquidates it to chase a single defence stock his cousin’s chartered-accountant friend is talking about at a Diwali card party. And it explains, more painfully, why the bulk of the ₹1.81 lakh crore of net F&O losses that SEBI documented in its January 2025 study were sustained not by people trying to get rich, but by people trying to catch up.
What Munger Actually Meant by the Envy Tendency
Munger’s framing is sharper than the colloquial use of the word. He was not talking about admiring someone’s success. He was talking about a hard-wired evolutionary response in which your brain compares your relative status with the people around you — neighbours, classmates, brokers, anonymous handles on a stock-tip channel — and registers their outperformance as your loss. The pain of falling behind a peer is, neurologically, almost identical to the pain of an actual portfolio drawdown. Your bank balance has not moved. Your stocks are exactly where they were yesterday. But because a person you grew up with has just doubled his money in a six-month F&O trade, your mind books a real loss.
This is why Munger was so insistent that envy is more destructive than greed. Greed, at least, points you toward the thing you want. Envy points you toward whatever the other person is holding — which may be a gambling chip, a leveraged contract, a stock at twelve times sales with no earnings, or a structured product the seller does not understand. The envious investor does not pick instruments rationally; he picks them by reference to who else is making money on them.
Why Envy Is Especially Dangerous in Indian Markets Right Now
India is in a particularly dangerous moment for the envy tendency because three forces are stacked on top of each other. First, the small-cap and micro-cap indices have produced enough five-year stories that almost every Indian investor knows someone — personally, not abstractly — who has made multi-bagger money. Second, social media collapses the proof of those gains into screenshot form, so the evidence is intimate and unavoidable; you do not just hear that a friend made money, you see his ledger. Third, broker apps have removed the friction between feeling and action. The gap between “I feel I am falling behind” and “I have just bought 200 lots of weekly Nifty options” is now about eleven seconds.
Munger’s defence against this was almost monastic. In his hundred years he repeatedly said the secret of his happiness was that he had set extraordinarily low expectations of life and learned to take pleasure in the success of the people he respected, instead of pain from it. As an investing prescription this sounds soft. It is not. It is the operational difference between an investor who holds Titan Biotech, HDFC Bank, Bajaj Finance or Asian Paints for fifteen years and an investor who churns through forty stocks a year because each one feels insufficient compared to whatever someone else is bragging about.
The Three Specific Decisions Where Envy Destroys Indian Portfolios
The first decision is position sizing. The envious investor sizes positions not by conviction and Kelly-style fraction of capital, but by what would be required to “catch up” with a benchmark friend. If a colleague has made ₹20 lakh on a small-cap, the envious investor sizes the next idea to potentially make ₹20 lakh — which usually means too large a position in too small a company.
The second decision is time horizon. The healthy long-term investor judges a holding over a five- to ten-year window because that is the period across which fundamentals dominate price. The envious investor compresses the window to whatever interval his envy reference point is using — usually weekly or monthly. The same Titan Biotech stock that has compounded at 38% CAGR over the last decade gets sold in seven months because someone, somewhere, made a faster 60% on a defence counter.
The third decision is instrument selection. Envy almost always pushes investors out of equity ownership and into derivatives, because derivatives offer the only mathematical pathway to the catch-up speed envy demands. SEBI’s own data shows that 93% of individual F&O traders lose money over a three-year window, and the average loss is ₹1.10 lakh. The envy tendency is the cleanest single explanation for why otherwise rational salaried Indians keep walking into that statistic.
The Munger Antidote — Construct an Indifference Curve to Others’ Wealth
The remedy Munger proposed is brutal in its simplicity. He said you must, by act of will, build inside your own mind a setting in which other people’s investment returns simply do not register as personal information. This is harder than it sounds because the comparison instinct is so deeply wired. The practical version of this I have arrived at, after watching investors for two decades, has four pieces.
First, never let anyone tell you their absolute rupee gains; only their methodology. Methodology you can learn from. Rupee gains will only make you envious. Second, benchmark your portfolio only against the Nifty 500 TRI over rolling five-year windows — not against your friend’s WhatsApp screenshots. Third, when you feel the envy spike, deliberately pull up the audited five-year ROCE of the businesses you own. Real numbers are an antidote to imagined narratives. Fourth, accept that envy is not eliminable; it is only manageable. Munger, who was perhaps the most rational living human in this century, said he still felt it. He just stopped acting on it.
How Titan Biotech’s FY25 Numbers Illustrate Anti-Envy Corporate Behaviour
Now let me show you what an envy-resistant operating philosophy looks like inside an actual Indian small-cap, using Titan Biotech Limited (BSE: 524717) and its FY25 audited annual report. The relevant point is not the stock price. The relevant point is that an investor’s envy problem is mirrored, at corporate scale, by a management’s envy problem — and a management that has refused to chase its peers is a powerful filter for capital allocation discipline.
Titan Biotech closed FY25 with a gross block of approximately ₹57 crore and capital work-in-progress of approximately ₹11 crore. That is a CWIP-to-gross-block ratio of about 19%. Read that number against the listed-specialty-biotech peer set in India over the last three years and what you see is a management that has not been pulled by envy into a doubling of capacity simply because a competitor announced a new plant. The capex pipeline is sized to what the business can absorb, not to what the press release of a rival demands.
The debt-to-equity ratio sits at approximately 0.02x, with borrowings of roughly ₹3 crore against a shareholder-equity base that has compounded over a decade. This matters because envy in a corporate context expresses itself almost always as leverage — a management that wants to grow at someone else’s pace, instead of its own, borrows. Titan Biotech did the opposite. Between FY15 and FY25 it moved from a net-debt to a net-cash position, with cash and investments of approximately ₹38 crore by year-end FY25.
The promoter holding stands at approximately 55.87% with zero pledging — a stake that has been creeping up over recent quarters, not down. A promoter group that is envious of someone else’s listed empire would have used this period of market enthusiasm to issue preferential allotments or dilute holdings into a private wealth corner. The opposite has happened: insider ownership has consolidated.
The dividend track record extends, unbroken, for fourteen years. Envy at the management level often expresses itself as withholding dividends to fund larger-than-warranted projects intended to “match” a competitor. Titan Biotech’s payout discipline indicates a board that has decided to share cash flow with shareholders even while the company has been compounding revenue at roughly a low-double-digit rate.
The ROCE for FY25 sits in the high-teens band, and the CFO-to-EBITDA ratio came in at approximately 103% — meaning more cash flowed out of operations than the accounting profit suggested. That second number is critical. A management driven by envy will report aggressive accounting profit to look competitive in headline league tables. Titan Biotech’s cash-conversion profile suggests the opposite reflex: conservative reporting that produces understated headline numbers and real cash on the balance sheet.
Finally, the export revenue mix sits at approximately 34.5% across 60-plus countries. An envious management would have funnelled marketing capital toward whatever vertical the listed-pharma celebrities were currently celebrated in. Titan Biotech instead diversified geographically — a slower, less glamorous path that does not produce envy-bait headlines but does produce a more resilient revenue base.
Stack these six audited markers — 19% CWIP-to-gross-block, 0.02x debt-to-equity, 55.87% promoter holding with zero pledge, fourteen years of unbroken dividends, 103% CFO/EBITDA, and 34.5% export share — and what you are reading is an audited corporate profile that behaves as though it has been immunised against Munger’s envy tendency. The board and management have refused, FY after FY, to allocate capital in response to peer envy. That refusal is the single most consequential discipline a long-term investor can demand from a small-cap holding.
The Takeaway
Envy is the most underrated wealth-destruction force in Indian markets because it does not announce itself. It does not feel like envy when it is happening. It feels like ambition, like urgency, like a rational response to the world having moved on without you. But the moment your portfolio decisions start to be benchmarked against a friend’s WhatsApp screenshot instead of against your own five-year compounding target, you have outsourced your investment process to the strongest negative emotion the human brain produces. Munger’s response was to install an internal scorecard, refuse to acknowledge the external one, and treat the calm boredom of long compounding as a virtue rather than a weakness. Titan Biotech’s FY25 audited numbers happen to read as a corporate version of exactly that discipline. The principle generalises far beyond any single company — the investor who masters envy is the investor who keeps his good positions long enough to let compounding do the only thing it has ever done, which is to reward the people who refused to compare.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
